The SELECT trial strengthened this expansion by showing a 20% lower rate of fatal and non-fatal cardiovascular events among overweight or obese people with a history of heart disease but no diabetes, giving cardiologists reason to prescribe GLP-1s for heart protection beyond weight management
Because the Long R3 form interacts more freely with IGF-1 receptors, with minimal interference from IGFBPs, it is valued in studies examining growth-factor signaling cascades, metabolic responses, and regenerative mechanisms
Rapid weight loss can also affect body composition and hormone levels, including estrogen, which plays an important role in maintaining vaginal health and supporting protective lactobacillus bacteria, says registered dietician Lenia Lopez
Michelle Oravitz: Right
Int J Obes (2010) 34:38595
This common concern affects many patients using this GLP-1 receptor agonist for diabetes or weight management